ArticleBioactive materials2026
Precisely regulated physically-crosslinked carriers enable synergetic release of bioactive factors for MSC-mediated cartilage regeneration.
Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Articular cartilage has limited capacity for self-repair due to its avascular nature. Successful cartilage repair requires the harmonious integration of sufficient stem cell recruitment, an optimal local microenvironment and a sustained repair timeframe. Here, we present a biocompatible, physically crosslinked silk fibroin platform with tunable β-sheet content (5-50 %) via freeze-assembly. This platform enables flexible and precise tuning of drug release kinetics without chemical cross-linkers. This system allows controlled drug release durations ranging from 1 to 35 days, suitable for both hydrophilic (MSC affinity peptide, MAP, serving a pro-recruiting role) and hydrophobic (kartogenin, KGN, pro-differentiating role) drugs. In a rat cartilage defect model, a sustained 21-day MAP release profile was identified as optimal, achieving an unprecedented high density of MSC recruitment (∼2.34 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.